Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $32.29.
A number of equities research analysts have recently commented on DAWN shares. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday. Bank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Wedbush reiterated an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th.
Get Our Latest Stock Analysis on DAWN
Insider Activity at Day One Biopharmaceuticals
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $866,000. Charles Schwab Investment Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after acquiring an additional 64,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after acquiring an additional 57,601 shares during the period. Geode Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after acquiring an additional 136,458 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $725,000. 87.95% of the stock is owned by hedge funds and other institutional investors.
Day One Biopharmaceuticals Stock Performance
NASDAQ:DAWN opened at $7.22 on Wednesday. The firm’s fifty day moving average is $10.13 and its two-hundred day moving average is $12.40. The firm has a market cap of $731.78 million, a price-to-earnings ratio of -7.01 and a beta of -1.38. Day One Biopharmaceuticals has a one year low of $7.06 and a one year high of $18.07.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. As a group, equities research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
- Five stocks we like better than Day One Biopharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- What is a penny stock? A comprehensive guide
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- 3 Small Caps With Big Return Potential
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.